Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.

ABSTRACT: Neoadjuvant chemotherapy (NACT) outcomes vary according to breast cancer (BC) subtype. Since pathologic complete response is one of the most important target endpoints of NACT, further investigation of NACT outcomes in BC is crucial. Thus, identifying sensitive and specific predictors of treatment response for each phenotype would enable early detection of chemoresistance and residual disease, decreasing exposures to ineffective therapies and enhancing overall survival rates. We used liquid chromatography-high-resolution mass spectrometry (LC-HRMS)-based untargeted metabolomics to detect molecular changes in plasma of three different BC subtypes following the same NACT regimen, with the aim of searching for potential predictors of response. The metabolomics data set was analyzed by combini

SUBMITTER: Diaz C 

PROVIDER: S-EPMC9297806 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature